Department of Gynecologic Oncology and Reproductive Medicine, M. D. Anderson Cancer Center, Houston, USA.
Department of Biostatistics, M. D. Anderson Cancer Center, Houston, USA.
Ann Surg Oncol. 2024 May;31(5):3017-3023. doi: 10.1245/s10434-024-14986-7. Epub 2024 Feb 12.
To improve the detection and management of perioperative hyperglycemia at our tertiary cancer center, we implemented a glycemic control quality improvement initiative. The primary goal was to decrease the percentage of diabetic patients with median postoperative glucose levels > 180 mg/dL during hospitalization by 15% within 2 years.
A multidisciplinary team standardized preoperative screening, preoperative, intraoperative, and postoperative hyperglycemia management. We included all patients undergoing nonemergent inpatient and outpatient operations. We used a t test, rank sum, chi-square, or Fisher's exact test to assess differences in outcomes between patients at baseline (BL) (10/2018-4/2019), during the first phase (P1) (10/2019-4/2020), second phase (P2) (5/2020-12/2020), and maintenance phase (M) (1/2021-10/2022).
The analysis included 9891 BL surgical patients (1470 with diabetes), 8815 P1 patients (1233 with diabetes), 10,401 P2 patients (1531 with diabetes) and 30,410 M patients (4265 with diabetes). The percentage of diabetic patients with median glucose levels >180 mg/dL during hospitalization decreased 32% during the initiative (BL, 20.1%; P1, 16.9%; P2, 12.1%; M, 13.7% [P < .001]). We also saw reductions in the percentages of diabetic patients with median glucose levels >180 mg/dL intraoperatively (BL, 34.0%; P1, 26.6%; P2, 23.9%; M, 20.3% [P < .001]) and in the postanesthesia care unit (BL, 36.0%; P1, 30.4%; P2, 28.5%; M, 25.8% [P < .001]). The percentage of patients screened for diabetes by hemoglobin A1C increased during the initiative (BL, 17.5%; P1, 52.5%; P2, 66.8%; M 74.5% [P < .001]).
Our successful initiative can be replicated in other hospitals to standardize and improve glycemic control among diabetic surgical patients.
为了提高我们的三级癌症中心围手术期高血糖的检测和管理水平,我们实施了一项血糖控制质量改进计划。主要目标是在 2 年内将住院期间中位术后血糖水平>180mg/dL 的糖尿病患者比例降低 15%。
一个多学科团队对术前筛查、术中、术后高血糖管理进行了标准化。我们纳入了所有接受非紧急住院和门诊手术的患者。我们使用 t 检验、秩和检验、卡方检验或 Fisher 确切检验来评估基线(BL)(2018 年 10 月至 2019 年 4 月)、第一阶段(P1)(2019 年 10 月至 2020 年 4 月)、第二阶段(P2)(2020 年 5 月至 2020 年 12 月)和维持阶段(M)(2021 年 1 月至 2022 年 10 月)患者之间的结果差异。
分析纳入了 9891 例 BL 手术患者(1470 例糖尿病患者)、8815 例 P1 患者(1233 例糖尿病患者)、10401 例 P2 患者(1531 例糖尿病患者)和 30410 例 M 患者(4265 例糖尿病患者)。住院期间中位血糖水平>180mg/dL 的糖尿病患者比例在该计划实施期间降低了 32%(BL:20.1%;P1:16.9%;P2:12.1%;M:13.7%[P<.001])。我们还观察到术中中位血糖水平>180mg/dL 的糖尿病患者比例降低(BL:34.0%;P1:26.6%;P2:23.9%;M:20.3%[P<.001])和麻醉后护理单元(BL:36.0%;P1:30.4%;P2:28.5%;M:25.8%[P<.001])的比例降低。接受血红蛋白 A1C 筛查的糖尿病患者比例在该计划实施期间增加(BL:17.5%;P1:52.5%;P2:66.8%;M:74.5%[P<.001])。
我们成功的计划可以在其他医院复制,以标准化和改善糖尿病手术患者的血糖控制。